Clinical Trial Update: Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial comparing Fruquintinib to Bevacizumab in combination with Irinotecan liposome and Capecitabine as second-line therapy for a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Fruquintinib (fruquintinib)
• Irinotecan liposome (liposomal irinotecan)

Snippet

Sponsor: Liu Huang | Conditions: Colorectal Cancer (CRC) | Phase 2 | Status: NOT_YET_RECRUITING